S
Signe O R Wallenstein
Researcher at Novo Nordisk
Publications - 6
Citations - 447
Signe O R Wallenstein is an academic researcher from Novo Nordisk. The author has contributed to research in topics: Semaglutide & Randomized controlled trial. The author has an hindex of 2, co-authored 5 publications receiving 153 citations. Previous affiliations of Signe O R Wallenstein include Aalborg University.
Papers
More filters
Journal ArticleDOI
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Thomas A. Wadden,Timothy S. Bailey,Liana K. Billings,Melanie J. Davies,Melanie J. Davies,Juan P. Frias,Anna Koroleva,Ildiko Lingvay,Patrick M. O'Neil,Domenica Rubino,Dorthe Skovgaard,Signe O R Wallenstein,W. Timothy Garvey,Step Investigators +13 more
TL;DR: Among adults with overweight or obesity, once-weekly subcutaneous semaglutide compared with placebo, used as an adjunct to intensive behavioral therapy and initial low-calorie diet, resulted in significantly greater weight loss during 68 weeks.
Journal ArticleDOI
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Thomas R. Pieber,Bruce W. Bode,Ann Mertens,Young Min Cho,Erik Christiansen,Christin L. Hertz,Signe O R Wallenstein,John B. Buse,S Akın,N Aladağ,A A Arif,L J Aronne,S Aronoff,E Ataoglu,S H Baik,H Bays,P L Beckett,D Berker,S Bilz,B Bode,E W Braun,J B Buse,L H S Canani,Y M Cho,C H Chung,I Colin,J Condit,J Cooper,B Delgado,D C Eagerton,I N El Ebrashy,M H M F El Hefnawy,F G Eliaschewitz,M P Finneran,S Fischli,E Fließer-Görzer,J Geohas,N A Godbole,A Golay,S Gorban de Lapertosa,J L Gross,H L Gulseth,F Helland,H O Høivik,C Issa,E S Kang,C Keller,S H A Khalil,N H Kim,I J Kim,L J Klaff,Markus Laimer,J C LaRocque,S N Lederman,K-W Lee,W R Litchfield,M B Manning,A Mertens,E J Morawski,A V Murray,P R Nicol,T M O'Connor,Aytekin Oguz,S Ong,A Özdemir,E M Palace,B A Palchick,J Pereles-Ortiz,T Pieber,R Prager,V Preumont,E Riffer,L Rista,G Rudofsky,Ramazan Sari,A Scheen,B Schultes,J A Seo,S A Shelbaya,K Sivalingam,C H Sorli,S Stäuble,D A Streja,G T'Sjoen,Tamer Tetiker,L Van Gaal,C Vercammen,Mark Warren,D L Weinstein,D Weiss,A White,M Winnie,C Wium,Dilek Gogas Yavuz +93 more
TL;DR: The primary endpoint was achievement of HbA1c of less than 7% at week 52 and the confirmatory secondary efficacy endpoint was change in bodyweight from baseline to week 52, and safety was assessed in all participants who received at least one dose of study drug.
Journal ArticleDOI
Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
Leigh Perreault,Melanie J. Davies,Juan P. Frias,Peter N Laursen,Ildiko Lingvay,Sriram Machineni,Anette Varbo,John P.H. Wilding,Signe O R Wallenstein,Carel W. le Roux +9 more
TL;DR: Step 1, 3, and 4 collectively provide a robust assessment of the effects of semaglutide on glucose metabolism and prediabetes in a large cohort of adults with overweight/obesity while on treatment.
Journal ArticleDOI
983-P: Effect and Safety of Flexible Dose Adjustment with Oral Semaglutide vs. Sitagliptin in Type 2 Diabetes: PIONEER 7
John B. Buse,B Bode,Young Min Cho,Erik Christiansen,Christin L. Hertz,Ann Mertens,Signe O R Wallenstein,Thomas R. Pieber +7 more
TL;DR: Flexible dose adjustment with oral sema provided superior glycemic control and weight loss at week 52 vs. sita, and was well tolerated with safety consistent with the GLP-1RA class.
Journal ArticleDOI
Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
Ofri Mosenzon,W. Timothy Garvey,Dan Hesse,Anna Koroleva,Robert F. Kushner,Soo Lim,Ildiko Lingvay,Signe O R Wallenstein,Thomas A. Wadden,Carel W. le Roux +9 more
TL;DR: Overall weight loss with semaglutide was greater among early responders, but non-responders also achieved a clinically-relevant weight loss by week 68 if semagLutide treatment was continued.